ARK Investment Management LLC Boosts Stock Position in Twist Bioscience Corporation $TWST

Key Points

• ARK Investment Management LLC has increased its stake in Twist Bioscience Corporation by 2.5%, owning approximately 10.68% of the company with a total value of $235.47 million.
• Barclays and Evercore ISI have recently adjusted their price targets for Twist Bioscience, with Barclays lowering it from $45.00 to $40.00 while maintaining an "overweight" rating.
• Twist Bioscience reported a loss of $0.47 EPS for the last quarter, surpassing analysts' expectations, and reported revenues of $96.06 million.

ARK Investment Management LLC grew its stake in Twist Bioscience Corporation (NASDAQ:TWST - Free Report) by 2.5% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 6,400,441 shares of the company's stock after purchasing an additional 158,846 shares during the period. Twist Bioscience makes up about 1.7% of ARK Investment Management LLC's holdings, making the stock its 15th largest holding. ARK Investment Management LLC owned approximately 10.68% of Twist Bioscience worth $235,472,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also recently added to or reduced their stakes in TWST. GAMMA Investing LLC lifted its holdings in Twist Bioscience by 68.1% in the first quarter. GAMMA Investing LLC now owns 748 shares of the company's stock valued at $29,000 after acquiring an additional 303 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Twist Bioscience by 15.0% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,315 shares of the company's stock valued at $85,000 after acquiring an additional 302 shares during the last quarter. Bayforest Capital Ltd lifted its holdings in Twist Bioscience by 49.3% in the first quarter. Bayforest Capital Ltd now owns 4,860 shares of the company's stock valued at $191,000 after acquiring an additional 1,604 shares during the last quarter. Vanguard Personalized Indexing Management LLC lifted its holdings in Twist Bioscience by 8.4% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 6,031 shares of the company's stock valued at $222,000 after acquiring an additional 469 shares during the last quarter. Finally, Hsbc Holdings PLC acquired a new position in Twist Bioscience in the first quarter valued at approximately $228,000.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on the company. Barclays decreased their price objective on Twist Bioscience from $45.00 to $40.00 and set an "overweight" rating on the stock in a report on Thursday, October 2nd. Weiss Ratings reiterated a "sell (d-)" rating on shares of Twist Bioscience in a report on Wednesday, October 8th. Cowen reiterated a "buy" rating on shares of Twist Bioscience in a report on Monday, August 4th. Finally, Evercore ISI decreased their price target on Twist Bioscience from $46.00 to $42.00 and set an "outperform" rating on the stock in a research note on Tuesday, October 7th. Nine investment analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $48.56.

Twist Bioscience Stock Up 2.0%

NASDAQ:TWST opened at $33.39 on Wednesday. The company has a quick ratio of 3.60, a current ratio of 3.90 and a debt-to-equity ratio of 0.03. The stock's fifty day moving average is $28.20 and its two-hundred day moving average is $32.22. Twist Bioscience Corporation has a 52 week low of $24.07 and a 52 week high of $55.33. The stock has a market capitalization of $2.02 billion, a price-to-earnings ratio of -23.03 and a beta of 2.38.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last released its quarterly earnings results on Monday, August 4th. The company reported ($0.47) EPS for the quarter, topping analysts' consensus estimates of ($0.54) by $0.07. The company had revenue of $96.06 million for the quarter, compared to analysts' expectations of $95.52 million. Twist Bioscience had a negative return on equity of 29.03% and a negative net margin of 23.51%. Twist Bioscience has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. Research analysts anticipate that Twist Bioscience Corporation will post -2.12 EPS for the current year.

Insiders Place Their Bets

In other news, CFO Adam Laponis sold 2,517 shares of the stock in a transaction on Thursday, October 9th. The stock was sold at an average price of $32.92, for a total value of $82,859.64. Following the sale, the chief financial officer directly owned 91,525 shares in the company, valued at approximately $3,013,003. This trade represents a 2.68% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Dennis Cho sold 3,876 shares of the stock in a transaction on Monday, October 6th. The shares were sold at an average price of $32.19, for a total value of $124,768.44. Following the completion of the sale, the insider owned 98,710 shares in the company, valued at approximately $3,177,474.90. The trade was a 3.78% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 64,368 shares of company stock valued at $2,036,204. 3.01% of the stock is owned by company insiders.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.

Want to see what other hedge funds are holding TWST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Twist Bioscience Corporation (NASDAQ:TWST - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.